Literature DB >> 18846360

[Venous interventions. Part 2: Thromboses of the upper torso and mesenteric veins].

L Kamper1, K Krüger, A Altenburg, M Mansour, P Landwehr, P Haage.   

Abstract

This article focuses on the percutaneous treatment options of venous thromboses and occlusions. Interventional therapy modalities for mediastinal, brachial, axillar, cerebral, and mesenteric thromboses are reviewed. Stenoses of the superior vena cava are most often caused by mediastinal malignomas. Balloon angioplasty together with stent implantation is an effective method for revascularisation in cases of upper venous congestion. Benign central venous stenoses are common in dialysis patients for whom interventional therapy using balloon angioplasty has proven excellent results. In the treatment of insufficient dialysis access, percutaneous techniques represent the first-choice option. Regarding cerebral and mesenteric thrombosis, interventional therapy is restricted to selected individual cases.

Entities:  

Mesh:

Year:  2009        PMID: 18846360     DOI: 10.1007/s00117-008-1750-6

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  10 in total

1.  Rapid thrombectomy of superior sagittal sinus and transverse sinus thrombosis with a rheolytic catheter device.

Authors:  M J Opatowsky; P P Morris; J D Regan; J D Mewborne; J A Wilson
Journal:  AJNR Am J Neuroradiol       Date:  1999-03       Impact factor: 3.825

2.  Paget-Schroetter syndrome: what is the best management?

Authors:  H C Urschel; M A Razzuk
Journal:  Ann Thorac Surg       Date:  2000-06       Impact factor: 4.330

3.  EBPG on Vascular Access.

Authors:  Jan Tordoir; Bernard Canaud; Patrick Haage; Klaus Konner; Ali Basci; Denis Fouque; Jeroen Kooman; Alejandro Martin-Malo; Luciano Pedrini; Francesco Pizzarelli; James Tattersall; Marianne Vennegoor; Christoph Wanner; Piet ter Wee; Raymond Vanholder
Journal:  Nephrol Dial Transplant       Date:  2007-05       Impact factor: 5.992

Review 4.  Radiological central vein treatment in vascular access.

Authors:  M Mansour; L Kamper; A Altenburg; P Haage
Journal:  J Vasc Access       Date:  2008 Apr-Jun       Impact factor: 2.283

5.  Use of a microsnare to aid direct thrombolytic therapy of dural sinus thrombosis.

Authors:  L J Bagley; R W Hurst; S Galetta; J Teener; G P Sinson
Journal:  AJR Am J Roentgenol       Date:  1998-03       Impact factor: 3.959

Review 6.  Nontraumatic vascular emergencies: imaging and intervention in acute venous occlusion.

Authors:  Patrick Haage; Timo Krings; Thomas Schmitz-Rode
Journal:  Eur Radiol       Date:  2002-08-22       Impact factor: 5.315

Review 7.  [Interventional radiology in central venous obstructions. Dilatation--stent implantation--thrombolysis].

Authors:  K Mathias; H Jäger; J Willaschek; B Theophil
Journal:  Radiologe       Date:  1998-07       Impact factor: 0.635

8.  Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients.

Authors:  P Haage; D Vorwerk; W Piroth; K Schuermann; R W Guenther
Journal:  Radiology       Date:  1999-07       Impact factor: 11.105

9.  Percutaneous treatment of thrombosed primary arteriovenous hemodialysis access fistulae.

Authors:  P Haage; D Vorwerk; J E Wildberger; W Piroth; K Schürmann; R W Günther
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

10.  Venous stenosis and occlusion in hemodialysis shunts: follow-up results of stent placement in 65 patients.

Authors:  D Vorwerk; R W Guenther; H Mann; K Bohndorf; P Keulers; G Alzen; M Sohn; D Kistler
Journal:  Radiology       Date:  1995-04       Impact factor: 11.105

  10 in total
  2 in total

1.  [Targeted diagnosis of mesenteric ischemia].

Authors:  Sven Winkler; Lars Kamper; Stefanie Jansen; Nadine Abanador-Kamper; Werner Piroth; Patrick Haage
Journal:  Med Klin (Munich)       Date:  2009-12-15

2.  [Treatment of mesenterial vein thrombosis].

Authors:  F Schellhammer; G Fürst
Journal:  Radiologe       Date:  2009-09       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.